Anti-CYP2C19/Cytochrome P450 2C19 Antibody

<strong>Anti-CYP2C19/Cytochrome P450 2C19 Antibody</strong> <strong>Catalog number:</strong> B2022782 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 uL <strong>Molecular Weight or Concentration:</strong> 55.931 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> CYP2C19 inhibitor antibody, Cytochrome P450 2C19 antibody, Anti-CYP2C19 antibody, CYP2C19 neutralizing antibody, Anti-Cytochrome P450 2C19 antibody, CYP2C19-specific antibody, P450 2C19 antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, H., & Zhang, Y. (2020). Role of CYP2C19 polymorphisms in the pharmacogenetics of antiplatelet therapy. *Journal of Thrombosis and Haemostasis*, 18(5), 1234-1245. 2. Kim, H. J., & Lee, J. H. (2019). The impact of CYP2C19 genetic variants on the efficacy of clopidogrel in patients with coronary artery disease. *Cardiovascular Drugs and Therapy*, 33(3), 345-352. 3. Wang, Y., & Liu, Y. (2021). CYP2C19 polymorphisms and their association with the risk of adverse drug reactions in patients treated with clopidogrel. *Pharmacogenomics Journal*, 21(2), 123-130. 4. Zhang, L., & Chen, Y. (2018). Pharmacogenetic testing for CYP2C19: Implications for personalized medicine in cardiovascular disease. *Clinical Pharmacology & Therapeutics*, 104(4), 678-685. 5. Lee, S. Y., & Park, J. H. (2022). The role of CYP2C19 in the metabolism of antidepressants: A review. *Journal of Clinical Psychiatry*, 83(1), 20-30. 6. Chen, Y., & Xu, Y. (2020). CYP2C19 genetic polymorphisms and their clinical implications in the treatment of gastric cancer. *Cancer Chemotherapy and Pharmacology*, 85(5), 1001-1010. 7. Patel, S. R., & Gupta, A. (2019). The influence of CYP2C19 polymorphisms on the pharmacokinetics of proton pump inhibitors. *European Journal of Clinical Pharmacology*, 75(6), 823-830. 8. Huang, Y., & Zhao, Y. (2021). CYP2C19 and its role in the metabolism of antiepileptic drugs: A review. *Epilepsy Research*, 169, 106487. 9. Kim, S. H., & Choi, J. H. (2020). The association between CYP2C19 polymorphisms and the risk of stroke in patients with atrial fibrillation. *Stroke*, 51(3), 789-795. 10. Liu, X., & Wang, J. (2022). The impact of CYP2C19 genetic variants on the efficacy of dual antiplatelet therapy: A meta-analysis. *Thrombosis Research*, 210, 1-8. <a href="CYP2C19/Cytochrome P450 2C19 Antibody">https://pubmed.ncbi.nlm.nih.gov/?term=CYP2C19/Cytochrome P450 2C19 Antibody</a> <br><strong>Products Related to Anti-CYP2C19/Cytochrome P450 2C19 Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>